Physician profile
Hemant R Boolani
NPI 1952557753
$2,778.20
in general payments reported to CMS, 2019-2025
25 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $137 · 2021: $104 · 2022: $464 · 2023: $339 · 2024: $450 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $362.53 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $345.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $337.30 | 2019-2025 | |
| Abbott Laboratories | $279.73 | 2022-2023 | Jot Dx, Gallant, Aveir |
| Edwards Lifesciences Corporation | $213.69 | 2021-2025 | Sapien 3 Ultra Resilia, Pascal |
| E.R. Squibb & Sons, L.L.C. | $192.89 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $171.97 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $123.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $107.86 | 2019-2024 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.50 | 2020-2023 | Lifevest |
| Medtronic, INC. | $76.20 | 2021-2025 | Linq II, Micra |
| Janssen Pharmaceuticals, INC | $62.43 | 2019-2020 | |
| Bridgebio Pharma, INC. | $56.36 | 2025 | Attruby |
| Boston Scientific Corporation | $52.41 | 2024-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $51.14 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.39 | 2025 | Verquvo |
| Amarin Pharma, INC. | $30.88 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $29.58 | 2019-2025 | Onpattro |
| Astellas Pharma US INC | $28.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.51 | 2025 | |
| Lundbeck LLC | $23.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.76 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.55 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $17.25 | 2025 | |
| Siemens Medical Solutions USA, INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Boolani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.